Roche Holding AG (ETR:RHO)
Germany · Delayed Price · Currency is EUR | Market Cap | 278.83B +26.3% |
| Revenue (ttm) | 68.05B +1.5% |
| Net Income | 13.83B +55.6% |
| EPS | 17.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.15 |
| Forward PE | 15.48 |
| Dividend | 11.96 (3.35%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 250 |
| Average Volume | 211 |
| Open | 359.60 |
| Previous Close | 356.40 |
| Day's Range | 356.00 - 359.60 |
| 52-Week Range | 272.60 - 420.80 |
| Beta | n/a |
| RSI | 49.35 |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
The drugmaker's on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Roche gets second European approval for Alzheimer's test
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and design...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from ...
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign developed in partnership with adv...
Europe risks falling further behind in medicine race, warns Roche CEO
Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief E...
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche sales fell 5% in the first quarter, but increased 6% in constant exchange rates. The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on...
Roche Backs Full-Year View as Quarterly Sales Rise
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmac...
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals while data released on Wednes...
Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Basel, 22 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that feneb...
Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which ...
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 6...
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspry...
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupus
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the compa...
Roche launches new Elevidys study after feedback from European regulator
Roche on Thursday said it is initiating a late stage study for its gene therapy Elevidys following feedback from the European drug regulator. The therapy for duchenne muscular dystrophy (DMD), for w...
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in...
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.